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Abstract: Nowadays, people are living much longer than they used to do, however they are not free from ageing. Ageing, an inexorable 
intrinsic process that affects all cells, tissues, organs and individuals, is a post-maturational process that, due to a diminished homeostasis 
and increased organism frailty, causes a reduction of the response to environmental stimuli and, in general, is associated to an increased 
predisposition to illness and death. However, the high incidence of death due to infectious, cardiovascular and cancer diseases underlies a 
common feature in these pathologies that is represented by dysregulation of both instructive and innate immunity. Several studies show 
that a low-grade systemic inflammation characterizes ageing and that inflammatory markers are significant predictors of mortality in old 
humans. This pro-inflammatory status of the elderly underlies biological mechanisms responsible for physical function decline and age-
related diseases such as Alzheimer's disease and atherosclerosis are initiated or worsened by systemic inflammation. Understanding of the 
ageing process should have a prominent role in new strategies for extending the health old population. Accordingly, as extensively 
discussed in the review and in the accompanying related papers, investigating ageing pathophysiology, particularly disentangling age-
related low grade inflammation, is likely to provide important clues about how to develop drugs that can slow or delay ageing. 
Keywords: Ageing, age-related diseases, diet, drug, inflammation, longevity. 
INTRODUCTION 
 Nowadays, people are living much longer than they used to do, 
however they are not free from ageing. Ageing, an inexorable 
intrinsic process that affects all cells, tissues, organs and 
individuals, is a post-maturational process that, due to a diminished 
homeostasis and increased organism frailty, causes a reduction of 
the response to environmental stimuli and, in general, is associated 
to an increased predisposition to illness and death. Actually, it is 
characterized by a state of reduced ability to maintain health and 
general homeodynamics of the organism. Why we age is a question 
answered by evolutionary biologists in terms of allocation of 
resources, and by gerontologists in terms of damage and repair. 
However, the ageing phenotype is a complex inter-action of 
stochastic, environmental, genetic and epigenetic variables. These 
variables do not create the ageing phenotype but generate the lack 
of molecular fidelity and therefore as the random accumulation of 
damage in the human organism's cells, tissues, or whole organism 
during life increases, the probability of disease and death also 
augments in proportion [1-4].  
 In the Western countries, if we compare the mortality rate in 
people over 65 years, versus individuals ranging between 25 and 44 
years, it increases to 100-fold for stroke, and chronic lung disease, 
92-fold for heart disease, 89-fold for pneumonia and influenza and 
43-fold by cancer [1]. Common observation tells us that even the 
apparently healthy people differ in the length of healthy, or 
successful, ageing period. Some experience healthy state until their 
seventies or eighties, while some others, the centenarians, last than 
hundred years. Thus, one of the crucial questions posed by 
gerontologists is: why we do not age at the same rate and how could 
we predict the rate of ageing [5]. 
 However, the high incidence of death due to infectious, 
cardiovascular and cancer diseases underlies a common feature in 
these pathologies that is represented by dysregulation of both 
instructive and innate immunity. Several studies show that a low- 
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grade systemic inflammation characterizes ageing and that 
inflammatory markers are significant predictors of mortality in old 
humans. This pro-inflammatory status of the elderly underlies 
biological mechanisms responsible for physical function decline 
and age-related diseases such as Alzheimer's disease (AD) and 
atherosclerosis which are initiated or worsened by systemic 
inflammation [5-7]. 
 In the society, the public perception of advanced ageing 
involves the inability to survive due to chronic diseases and the 
combined loss of mobility, sensory functions, and cognition with an 
exponential growth of health costs linked to increased size of 
elderly in the Western World [8]. So, preventive therapeutic 
interventions to slow ageing are urgently needed. 
IMMUNOSENESCENCE 
 In the elderly, the waning of the immune responsiveness in the 
elderly renders this population increasingly susceptible to infectious 
diseases, leading to resurgence of latent infections, and also to 
supra-infection by opportunistic organisms. In this age group, these 
infections contribute significantly to morbidity, and frequently lead 
to irreversible frailty and dependency. However, the individual 
contributing factors to immunosenescence are many and varied, due 
to the multi-factorial complexity of the immune system. It is often 
difficult to determine whether changes in a particular cell type are 
intrinsic to that cell, or caused by environmental changes, or both. 
This is particularly the case for lymphocytes, where the interplay 
between B cells and T cells is crucial for effective responses, where 
if one subset is affected it will change the function of the other one 
[9-12].  
 Anecdotally, the clinical relevance of immunosenescence is 
well-documented, but exact detailed information is, in fact, hard to 
come by. Immunosenescence is a very vaguely-defined descriptive 
term covering the deleterious age-associated changes to immunity 
observed in all mammals studied so far. Early studies indicated that 
responses to mitogens predicted mortality to some degree, and since 
then many studies have probed associations between survival and 
parameters of both innate and acquired immunity. An emerging 
consensus suggests that maintenance of appropriate immunity is 
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essential for exceptional longevity and, by implication, also for 
"normal" longevity [9-12].  
 Lifelong and chronic antigenic load results one of the driving 
force of immunosenescence, by reducing the number of virgin 
antigen non-experienced T cells, and filling the immunological 
space with expanded clones of memory and effector, antigen 
experienced T cells. These cells are also responsible, at least in part, 
for the pro-inflammatory status of elderly through the cytokine 
production. In parallel with such an increase, the production T cell 
compartment tends to decline with age of about two orders of 
magnitude, and could be considered the other leading force of 
immunosenescence. In fact, T repertoire is generated and main-
tained by the thymic production and output of new T lymphocytes, 
naïve for their antigen. Such thymic activity is extremely efficient 
during childhood, but has a very low activity in the elderly. Thus, 
the repertoire of cells available to respond to antigenic challenge 
from previously unencountered pathogens is shrinking [9,13]. 
 Some mechanisms by which the immune system is maintained 
during ageing are discussed, paying particular attention to the 
crosstalk between the central organ, the thymus, where T cells 
come from, and the periphery, where T cells emigrate and exert 
their functions [14]. The different factors involved in the gene-
ration, maintenance and survival of the T cell pool hare considered. 
Several strategies aimed at improving thymic functionality are 
currently receiving a growing interest, and some of them are based 
on molecules that are produced by, and/or act on immune cells. 
Data on the possible use of these molecules, including cytokines 
like interleukin (IL)-7, IL-15 and keratinocyte growth factor, to 
restore thymic function are reviewed and discussed. The paper 
suggests that modulation of the functionality of the immune system 
by cytokines could also be useful to enhance cell-mediated 
immunity and to improve the responses to vaccines, but further 
studies are needed to achieve such an important goal [14].  
 Literature on immunosenescence has focused mainly on T cell 
impairment, but the B cell compartment is also affected in aged 
resulting in impaired quality of the antibody response. Until 
recently it was considered that the most likely cause of B cell 
failure was a lack of effective T cell help in a T-dependent reaction. 
However, there are T-independent functions of B cells, such as the 
polysaccharide responses that are crucial for anti-bacterial 
protection, which also appear to be lacking in later life. Changes in 
B cell number and repertoire have been described, and decreased 
IgM and IgD levels in the elderly suggest a shift from the naïve 
(CD27-) compartment of the B cell branch towards the memory 
(CD27+) compartment. However, these data are controversial since 
not all studies have shown this [10,15-17].  
 Recently, the IgD(-)CD27(-) double-negative B cell population, 
increased in the elderly, has been analysed, suggesting hat these 
expanded cells are late memory or exhausted cells that have down-
modulated the expression of CD27 and filled the immunologic 
space in the elderly. These cells might be the age-related 
manifestation of time-enduring stimulation or dysregulation of the 
immune system [18]. 
 To better characterize B cell immunosenescence, B cell 
compartment has been examined in two classes of individuals, old 
people and centenarian offspring [19]. In fact, it has been demons-
trated that the centenarian offspring, who are typically in their 70s 
and 80s, have a survival advantage when compared with age-
matched controls whose parents died at an average life expectancy 
[20,21]. As expected, in both cohorts a decreased B cell count has 
been observe. However, in centenarian offspring, naïve B cells are 
more abundant whereas exhausted memory cells (DN B cells, IgD-
CD27-) do not show the increase previously demonstrated in 
healthy elderly donors. These data are similar to that found in pre-
viously experiments on young subjects. So, these preliminary 
results show that centenarian offspring do not have the typical trend 
of memory/naive B cell subsets observed in elderly people and this 
is in agreement with the higher levels of IgM in the serum of 
centenarian offspring in comparison with data obtained in age-
matched controls. This reservoir of naive B cell might be one of the 
causes that make centenarian offspring able to keep fighting off 
new infections, hence prolonging their life. So, B cell subset 
changes could represent a hallmark of successful or unsuccessful 
ageing and could be used as a biomarker [19]. 
 In fact, to identify immunological biomarkers is an useful tool 
for antiageing strategies aimed to slow ageing and to postpone 
death by preventing infectious diseases [5].  
AGE-RELATED DISEASES & THERAPEUTICS 
 Most age-related diseases have complex aetiology and 
pathogenic mechanisms. A body of experimental and clinical 
evidence suggests that both innate and the clonotypic immune 
system are usually involved in the pathogenesis of these chronic 
diseases. However, inflammatory responses appear to be the 
prevalent triggering mechanism driving tissue damage associated 
with different age-related diseases and the term "Inflammaging" has 
been coined to explain the underlining inflammatory changes 
common to most age-associated diseases [6,7]. 
 The first line of immune defence mainly operates by detection 
of a broad range of molecular patterns foreign to mammalian 
tissues, called pathogen-associated molecular patterns that induce 
the activation of the innate immunity and inflammatory response. 
These germ cell-encoded proteins recognize microbial pathogens or 
ligands from damaged tissues based on shared molecular structures 
and induce host responses that localize the spread of infection and 
enhance systemic resistance to infection. Several cell types 
contribute to innate immunity and the mononuclear phagocyte 
lineage plays a pivotal role in innate immunity. Monocytes, macro-
phages and their tissue-differentiated derivatives, such as microglia 
in the nervous system, express pattern recognition receptors, 
namely various scavenger and Toll-like receptors (TLRs). TLR 
activation also induces the expression of a wide number of genes 
encoding proteins, such as cytokines, with regulatory functions 
upon leukocyte activation and tissue inflammation. Therefore, the 
capacity of each individual organism to regulate the activation of 
innate immunity and local inflammatory responses is crucial for 
initiating defensive action against pathogens, limiting tissue 
damage and enhancing fast recovery and tissue healing [6,7,22].  
 In response to cell injury elicited by trauma or infection the 
inflammatory response sets in, constituting a complex network of 
molecular and cellular interactions directed to facilitate a return to 
physiological homeostasis and tissue repair. The response is 
composed of both local events and a systemic activation mediated 
by cytokines. If tissue health is not restored or in response to stable 
low grade irritation, inflammation becomes a chronic condition that 
continuously damages the surrounding tissues. In fact, during 
chronic inflammatory immune responses, tissue injury and healing 
proceed simultaneously. The collateral damage caused by this type 
of inflammation usually accumulates slowly, some-times 
asymptomatically for years but can eventually lead to severe tissue 
deterioration [7,23].  
 Low grade inflammation has emerged as critical in the 
pathogenesis of several age-related chronic diseases as AD, 
atherosclerosis, type 2 diabetes, sarcopenia, frailty and functional 
disability. These diseases appear to be correlated, leading to the 
concept of an age-related disease, which may be linked by the 
process of inflammation. So, genes involved in the regulatory 
pattern of inflammation should play a role in human ageing, 
furthermore high serological levels of pro-inflammatory mediators 
like cytokines and C reactive protein seem to be the marker of 
unsuccessful ageing [6,7,24].  
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 However, a wide range of different aetiological factors is likely 
to contribute to increased low-grade inflammatory activity in 
elderly populations including the contribution of different tissues 
(adipose tissue, muscle), organs (brain, liver), immune system and 
ecosystems (gut microbiota) [25]. On the other hand, a recent 
hypothesis suggests that the reduction in lifetime exposure to 
infectious diseases and other sources of inflammation, the cohort 
mechanism, contributes to the historical decline in old-age mortality 
[26], pointing out long-life pathogen burden as the most important 
factor for age-related inflammation. Accordingly, some studies 
have linked an individual's exposure to past infection to levels of 
chronic inflammation and to increased risk of heart attack, stroke, 
and cancer [6,7,26]. 
 The oral cavity is involved in several physiologic activities, 
such as language, posture, mastication, swallowing, prosthetic 
retention. It has been established that the process of ageing includes 
a general progressive decline in the body’s total skeletal mus-
culature mass and its performance, which includes masticators and 
mimic facial muscles. Thus the aging process may lead to dramatic 
changes in the condition of teeth, oral mucosae, alveolar bone and 
salivary glands, even if age alone does not seem to play an exclu-
sive role in these impairments. Dental, periodontal, oral mucosal, 
and salivary diseases have a detrimental and compounding affect on 
oral health in elderly persons, yet oral disease is not necessarily a 
concomitant of growing older. Similarly, numerous systemic 
diseases, drugs, and other medical treatments can adversely affect 
oral functions in older adults. These disorders must be recognized 
and managed appropriately by health care practitioners who will be 
able to contribute to eradicating disease, restoring function, and 
improving the quality of a person’s life [27]. 
 On the other hand, persistent peripheral multibacteria infection 
such as periodontitis (PD), associated with gram-negative anaerobic 
bacteria capable of exhibiting localized and systemic infections in 
the host, has been proposed as possible aggravating cofactor in 
subjects with vascular disease. In PD the balance between bacteria 
and host response is altered, resulting in a production of high levels 
of pro-inflammatory mediators and low levels of anti-inflam-
matory ones. Locally, these molecules act in concert to amplify the 
inflammatory reaction and activate the effector mechanisms respon-
sible for tissue destruction. Moreover, inflammatory chemokines 
and cytokines are elevated in plasma of PD patients, thus, contri-
buting to the systemic inflammatory burden and exerting potential 
systemic effects. Data regarding the PD association with neuro-
degenerative disorders are lacking; however, it seems plausible that, 
during PD, cytokines increase in AD brain due to stimulation of 
trigeminal nerve fibres, or directly from bacterial products and/or 
bacteria. It seems relevant that in the NUN study a relationship 
between teeth loss and AD was found, but only in APO4 negative 
subjects [28-30]. 
 Buccal epithelium is a relatively permeable, robust non-
keratinized tissue and blood vessels drain directly into the jugular 
vein; due to its particular features, it has been of increasing interest 
to researchers as an alternative site of drug administration. Recent 
studies have investigated the delivery of a variety of drugs through 
the buccal mucosa in order to assess both local and systemic, either 
positive or adverse, effects. In conclusion, buccal mucosa might be 
considered a promising site for effective, safe and non-invasive 
transmucosal sustained drug delivery [31]. According to this 
hypothesis, interesting results have been obtained in an experi-
mental model on the in vivo trasbuccal delivery of galantamine, a 
drug used for in AD therapy. The in vivo animal trial has 
established the efficacy of an electronically-controlled device for 
the transbuccal drug delivery of galantamine. This could be a 
revolutionary approach to drug administration in AD even if further 
studies in vivo in human beings are required. Such an innovative 
approach could also be used for other types of medication that 
allows such non invasive transmucosal delivery although other 
experiments must be carried out for each candidate drug prior to 
deciding on the suitability of so called “IntelliDrug” approach [32]. 
 Finally, osteoarthritis (OA) is a very common inflammatory 
disease in the elderly. According to the American College of 
Rheumatology, nearly 70 percent of people over age 70 have X-ray 
evidence of OA, although only half ever develop symptoms. 
Notwithstanding, due to the huge amount of persons affected, OA is 
a frequent cause of disability [33]. The current therapeutic 
approaches with non-steroidal anti-inflammatory drugs (NSAIDs) 
or steroids do not delay the OA progression or reverse joint 
damage. Moreover, they may cause relevant systemic side effects. 
On the basis of the published trials, it is suggested that viscosupple-
mentation therapy with hyaluronic acid physiologic component of 
the synovial fluid and is reduced in OA joints is a safe and effective 
method in the management of OA resistant to conventional 
therapies. The use of hyaluronic acid is mainly recommended when 
NSAIDs are contraindicated or badly tolerated, when NSAIDs or 
steroids are inefficacious or in young patients who are candidates 
for prothesis [34].  
 The process of life for the individual is the struggle to preserve 
its biological and immunological integrity, nonetheless organism 
integrity comes with a price of responsiveness to systemic 
inflammation which must be finely tuned, otherwise dysregulation 
becomes a damaging accompany [1,7]. Inflammation is not 'per se' 
a negative phenomenon: it is the response of the immune system to 
pathogenic viruses or bacteria. Thorough out evolution, man has 
been set to live about 40 or 50 years but in today's world the 
immune system is active for several decades compared with the 
past centuries. This long period of activation may lead to chronic 
inflammation which inexorably damages several/all organs and is 
the phenotype linked to both ageing and chronic disease [6,7].  
 How can centenarians survive with inflammageing? Even if 
centenarians have an increased level of inflammatory mediators in 
comparison to old subjects and they are very frail, inflammageing is 
compatible with longevity (100 years of age or more); this paradox 
may be explained because centenarians have also high level of anti-
inflammatory cytokines and the protective genotype of important 
molecules (such as those belonging to natural immunity) [24], (see 
also below). Therefore, the most proper approach to tackle and 
manage inflammageing is to follow a sort of “mirror-strategy”: 
since inflammageing is a pleiotropic process where many different 
factors operate, in the same way pleiotropic interventions acting on 
different targets and at different levels at the same time are to be 
preferred and chosen, in a kind of mimic way [25].  
NEURODEGENERATION 
 AD is a progressive neurodegenerative illness affecting elderly 
people. In fact, the prevalence of AD rises exponentially from 1% 
at age of 65 to approximately 40-50% by the age of 95; it also 
represents a growing public health problem as life expectancy 
increases [35]. Initial manifestations of AD include subtle memory 
loss and forget-fulness, which progress to profound memory loss, 
cognitive dysfunction and behavioural and emotional disturbances 
that may eventually interfere with the patient’s ability to perform 
basic activities of daily living. The pathological hallmarks are 
neurofibrillary tangles and senile plaques. The former are mainly 
composed by a cytoskeletal protein named tau, which becomes 
hyperphosphorylated and self aggregates into neurofibrillary 
tangles. Senile plaques are characterized by the accumulation of 
proteins in the form of -pleated sheet fibrils, which are composed 
mainly of a 42 amino acids peptide known as -amyloid (A) [36]. 
In particular, the “amyloid cascade hypothesis” supports the idea 
that A is the main pathogenetic factor of AD because the aberrant 
metabolism of the amyloid precursor protein and the subsequent 
massive production and deposition of the peptide in extracellular 
sites are responsible for a concatenate series of events that have as a 
final result neurotoxicity and consequent neuronal death [37,38].  
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 In addition to its well-known neurotoxic role, recent evidences 
suggest A putative implication in regulating normal brain 
homeostasis, in which, under normal conditions, A may also play 
a key role in the regulation of synaptic activities and brain functions 
[39]. Actually, experimental evidence indicates that A peptides are 
constitutively produced by brain cells and are found in the nM-pM 
range in the cerebrospinal fluid of non-demented individuals and in 
media from neuronal cell cultures, suggesting that, as well as 
having a potential pathological role in AD, A peptides under 
normal conditions may have a role in the regulation of brain 
functions, consistent with their ubiquitous presence and normal 
synthesis. During normal ageing these neuromodulatory roles may 
be affected probably due to changes in the peptide burden, since A 
levels have reported to increase in this stage of life. Hence, it 
should be useful to explore whether the increased presence of this 
peptide in healthy aged subjects may predict a potential conversion 
to neurodegeneration, mainly towards AD. Nonetheless, the 
putative neuromodulatory role of A in the context of ageing is 
nowadays unknown. For these reasons, studies about A spectrum 
of action (brain areas and neurotransmitter systems affected) might 
suggest new therapeutic targets in order to sustain those functions 
which may be altered during ageing [39]. 
 AD prevention is an important goal of ongoing research. Two 
objectives must be accomplished to make prevention feasible: 1) 
individuals at high risk of AD need to be identified before the 
earliest symptoms become evident, by which time extensive 
neurodegeneration has already occurred and intervention to prevent 
the disease is likely to be less successful and 2) safe and effective 
interventions need to be developed that either reduce or slow the 
accumulation of AD neuropathology or lead to a decrease in 
clinical expression of this pathology [38,40].  
 Events contributing to AD development are numerous and 
complex. The pathogenesis involves a multitude of variables many 
of which remain to be quantified. Recent work highlighting the 
importance of neuroinflammation in AD, has led to the prospect of 
exciting future therapeutic options. A better understanding of the 
interplay between cytokines, their receptor activity, second 
messengers, lipid metabolism and protein modification is necessary. 
Although there are many events which can lead to neuroinflam-
mation, this process represents a common pathway of disease 
development [41].  
 Several inflammatory factors influencing AD development, i.e. 
environmental factors (pro-inflammatory phenotype) and/or genetic 
factors (pro-inflammatory genotype) have been described 
[36,40,42]. A growing number of studies in AD have also reported 
alterations in systemic immune responses including changes in 
lymphocyte distribution and activation. Studies in animal models 
support the notion that immune cells infiltrate the brain and may 
modulate the disease [43]. Moreover, variations in immune-
inflammatory genes such as cytokine, cyclooxygenase (COX), lipo-
oxygenease (LO), TLR have also been considered to be important 
in the risk for AD [36,40]. In particular, cytokine gene poly-
morphisms have been claimed to play a key role in pathophysiology 
of AD, as demonstrated by two recent meta-analysis performed on 
IL-1 and tumor necrosis factor(TNF)- [44,45]. However, data on 
a meta-analysis focused on IL-6, a pleiotropic cytokine involved in 
the regulation of the acute inflammatory response, do not seemingly 
support a role in AD pathophysiology [46]. However, it is to take 
into account that inflammatory mediators do not act alone but they 
act in a complex network reciprocally interacting [47]. Moreover, 
inflammation is strictly related to reactive oxygen species (ROS) 
production. Mammalian cells have developed highly regulated 
inducible defensive systems, whose cytoprotective functions are 
essential in terms of cell survival. When appropriately activated, 
each one of these systems has the possibility to restore cellular 
homeostasis and rebalance redox equilibrium. Activation of anti-
oxidant pathways is particularly important for tissue with relatively 
weak endogenous antioxidant defenses, such as the brain. Increa-
sing evidence, in fact, support the idea that reduction of cellular 
expression and activity of antioxidant proteins and consequent 
augment of oxidative stress play a central role in ageing processes 
and neurodegenerative diseases, including AD [5,42]. Regarding 
molecules with anti-oxidant properties, a number of experimental 
and epidemiological studies have recently supported the beneficial 
effects of some commonly used natural products in preventing 
various pathologic conditions ranging from cardiovascular diseases 
to cancer. Spices and herbs often contain phenolic substances with 
potent anti-oxidative and chemopreventive properties. Among 
others, curcumin seems to have a possible role in AD [38,46], 
playing several mechanisms. However, it is able to clear amyloid 
via the induction of heat shock proteins (HSPs), that function as 
molecular chaperones to block protein aggregate formation. 
Recently curcumin has been evaluate in a pilot clinical trial in AD 
patients, with preliminary encouraging results [38]. So, further in 
vitro and in vivo studies using curcumin-like molecules will give 
important information on the feasibility of developing new 
pharmacological strategies [46].  
 As above discussed, AD patients show impaired memory and 
cognitive functions. Although several neurochemical deficits have 
been described, explanation of the nature of the cognitive distur-
bance is focused on the "cholinergic hypothesis". The AD symp-
toms are the direct consequence of a severe deficit in the 
cholinergic neurotransmission following a progressive degeneration 
in forebrain and, in particular, in the nucleus basalis mag-
nocellularis (NBM) [48,49]. The degeneration of cell bodies in 
NBM causes the loss of neuronal cortex projections accompanied 
by a reduction of the brain levels of the neurotransmitter acetyl-
choline (ACh) and the biosynthetic enzymes choline acetyl trans-
ferase and acetylcholinesterase [50,51]. Many different strategies 
have been investigated to improve cholinergic neurotransmission, 
including the reduction of synaptic ACh hydrolysis by Choline-
sterases inhibition and the increase of ACh synthesis. In an 
integrated study to develop simple choline esters as cholinergic 
agents potentially useful against AD. Simple derivatives, such as 
the choline esters, have been shown to exert pharmacological 
effects in vivo models restoring the cortical activity similar to that 
obtained with anticholinergic agents, such as tacrine or donepezil, 
currently used in the anti AD palliative therapy [52]. 
 In regard to the molecular and cellular mechanisms that 
determine whether brain ageing occurs successfully or manifests 
dysfunction or disease, the major classes of signalling molecules 
important in brain ageing include neurotrophic factors (NFTs), 
neurotransmitters, cytokines and steroids. In particular, an impor-
tant role in balancing protective/neurodegenerative processes is 
played by NFTs, which are central to many aspects of nervous 
system function since they regulate the development, maintenance 
and survival of neurons and neuron-supporting cells such as glia 
and oligodendrocytes. A vast amount of evidence indicates that 
alterations in levels of NFTs or their receptors can lead to neuronal 
death and contribute to ageing as well as to the pathogenesis of 
neurodegenerative diseases such as AD. On the other hand, data of 
recent human clinical studies and trials are available unraveling 
NFT therapeutic potential in a variety of diseases states and ageing. 
In particular, nerve growth factor, brain-derived neurotrophic 
factor, glial-cell-line-derived neurotrophic factor, insulin-like 
growth factor I and ciliary neurotrophic factor have been examined. 
NTFs have been shown to promote the survival of specific 
populations of brain neurons under experimental conditions 
relevant to brain aging and neurodegenerative disorders. NTFs exert 
their effects on the development and function of neurons by binding 
to cell surface receptors possessing intrinsic tyrosine kinase 
activity, in turn activating down-stream kinases including the 
phosphatidylinositol-3-kinase, protein kinase C, and the mitogen-
activated protein kinase, as well as several small G-proteins 
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[53,54]. As a consequence, some transcription factors are activated 
and ultimately the expression of genes that encode proteins 
involved in regulating neuronal survival, differentiation and 
plasticity is induced. Cellular and molecular mechanisms by which 
neurotrophic factors may influence cell survival and excitability are 
also critically examined to provide novel concepts and targets for 
the treatment of physiological changes bearing detrimental func-
tional alterations and of different diseases affecting the central 
nervous system during ageing [53]. 
 The role of the so-called cognitive kinases and the importance 
of their age-related alterations has been examined [55]. In fact, 
considering the critical implication of protein kinases in converting 
the extracellular signals into biological responses, it is logic to 
hypothesize that their functional alterations may directly contribute 
to age-dependent neuronal dysfunctions thus reverberating on 
memory processes. Within this context, numerous studies point out 
on several kinases as positive regulators for memory function and 
suggest that various memory disturbances are the result of a deficit 
in kinase signalling pathways. Many kinases associated with 
synaptic function are indeed age-sensitive; in fact, various studies 
in aged animals indicate that a reduction in kinases expression/ 
function in some brain areas correlates with ageing and memory 
decline. Within the large family of kinases involved in signal 
transduction, which have been studied in relation to ageing, 
memory and cognition, Protein Kinase C, Protein Kinase A, 
Calcium/calmodulin-dependent Protein Kinase, Tyrosine Kinase, 
are widely accepted as key actors in signalling pathways associated 
with memory. In line with these concepts, pharmacological 
modulation of kinases may lead to neuroprotective effects that can 
prevent or counteract age-related memory impairment [55].  
 However, taking into account the future epidemics of AD 
[35,36], studies on pathophysiology of AD opening the way for 
new diagnostic approaches for early diagnosis hence preventive 
treatment are welcome.  
CANCER AND AGEING 
 In most mammalian species carefully examined, cancer 
incidence goes up with roughly exponential kinetics, starting at 
about the average of the lifespan [56]. So, cancer is generally 
recognized as an age-related disease; the median age for cancer 
diagnosis in industrialized countries is nearly 70 years of age and is 
expected to increase [57]. This might be due to a common biology 
that links cancer and ageing or cancer might merely represent a 
coincidental correlate of ageing, i.e. due to an increased duration of 
carcinogenesis [56,58]. However, incidence and mortality rates of 
most human cancers consistently increase up to age 90, but they 
plateau and decline thereafter, suggesting that centenarians are 
protected from developing cancer. Accordingly, cancer deaths 
account for 40% from age 50 to 70 and less than 4% for centenarian 
people [59]. Actually, centenarians, their offspring and siblings 
have better chances to escape major age related disease including 
cancer [60]; autoptic studies clearly show that, in centenarians, the 
cause of death by cancer and metastatic spread are lower than 
expected [61].  
 An increase in somatic mutations has been documented in aged 
cells, and presumably relates to cumulative lifetime exposure to 
endogenous and exogenous DNA damaging agents, as well as to an 
accumulation of mutations during DNA replication [59,62]. How-
ever, as previously stated, in oldest old individuals cancer pre-
valence does not increase, but declines, despite the longer exposure 
to exogenous and endogenous factors causing cancer. 
 As previously stated, a low-grade systemic inflammation 
characterizes ageing and this pro-inflammatory status underlies 
biological mechanisms responsible for age-related inflammatory 
diseases, including cancer [59,62]. Another mechanism responsible 
might be the reduced immune function, i.e., immunosenescence in 
the elderly [63]. The importance of the immune system in 
preventing tumor formation, immunosurveillance, is supported by 
epidemiological evidence [64].  
 Clinical and epidemiologic studies have suggested a strong 
association between chronic infection, inflammation, and cancer; it 
is known that alcohol abuse can lead to liver and pancreatic cancer, 
smoking to airway inflammation and lung carcinoma, and 
infectious disease such as hepatitis C virus or papilloma infections 
to liver and cervical cancer [59,62]. In addition, many other 
inflammatory triggers are associated with other malignancies, 
including microbial infection, such as Helicobacter pylori infection, 
associated with gastric cancer, autoimmune responses associated 
with inflammatory bowel disease and colorectal cancer and sexual-
transmitted infections with prostatitis and prostate cancer [65-67].  
 Inflammation seems to play a role in carcinogenesis by causing 
cellular and genomic damage, promoting cellular turnover, and 
creating a tissue microenvironment that can enhance cell repli-
cation, angiogenesis and tissue repair. Actually, tumors are thought 
to develop from chronic inflammation, where uncontrolled cell 
proliferation occurs in a milieu rich in pro-inflammatory cytokines, 
inflammatory mediators, and growth factors normally involved in 
chronic and unresolved inflammation. In normal tissues, anti-
inflammatory cytokines are synchronically upregulated after the 
pro-inflammatory cytokines are produced, leading to inflammation 
resolution. In chronic inflammation, this does not occur, resulting in 
a continuous production of ROS, leading to oxidative DNA damage 
and reduced DNA repair, and increased proliferation [59,62,68,69]. 
 In this framework, an interesting model is represented by 
prostate cancer (Pca), which is featured by a complex patho-
physiology with a strong genetic component. Multiple genes seem 
to influence Pca risk and several single nucleotide polymorphisms 
(SNPs) of candidate genes modifying Pca susceptibility have been 
identified. It is noteworthy the potential association of common 
SNPs in pro-inflammatory genes with Pca risk, since chronic 
inflammation is assumed to play a key role also in prostate 
carcinogenesis. With the aim to identify candidate genes in order to 
develop new strategies for both prevention and treatment of Pca, it 
has been investigate the potential role of common SNPs of a gene 
cluster, TLR-4, TLR-2, COX-2 and 5-Lo, involved in innate and 
inflammatory response, has been investigated in Pca cases, age-
matched controls and centenarians from Sicily [70]. Statistical 
analysis evidenced a significant association of some pro-inflam-
matory gene SNPs with an increased risk of Pca. In particular, the 
use of centenarians as “super-controls” [62] enhanced the pos-
sibility of identifying the genetic profile characterizing suscep-
tibility and/or resistance to Pca. 
 On the other hand, it is well established that an increase of n-6 
polyunsaturated (i.e. arachidonic and arachidonic–converted lino-
leic acids) fat dietary intake enhances carcinogenesis and promotes 
tumorigenesis through oxidative metabolism. By contrast, n-3 
polynsaturated fatty acids (i.e. fish oil) have antitumorigenic effects 
[71-75]. It is generally known that COX and LO enzyme classes 
mediate the oxidative metabolism of n-6 polyunsaturated fatty acids 
and generate a cascade of biological active inflammatory molecules 
also implicated in tumor development are overexpressed during 
carcinogenesis [59,62]. NSAIDs modulating arachidonic acid 
metabolism have been utilized in cancer chemoprevention [59,62]. 
The gastrolesivity of a prolonged use of nonselective NSAIDs, due 
to the COX inhibition, an important housekeeping gene of the 
gastrointestinal system, contraindicated their use in chemo-
prevention. Moreover, cardiovascular side effects emerged in the 
long-term use of COX-2 specific inhibitors rising doubts on their 
use for cancer chemoprevention [76-78]. In light of these recent 
observations, the development of novel cancer chemoprevention 
strategies is necessary and LO-inhibitors could be of interest. 
However, data obtained with tumor cell lines indicate that multiple 
drug combination of distinct COX-2 and 5-LO inhibitors at 
clinically feasible concentrations were more effective than each 
Inflammation and Successful Ageing Current Pharmaceutical Design, 2010, Vol. 16, No. 6    589 
agent alone. Larger clinical trials are necessary to confirm the 
clinical effectiveness and safety of COX/LO dual inhibitors and to 
define the possibilities of widespread use, especially in “frail” 
patients, in which age-related pluripathologies were present [79]. 
 As previously stated, viral infections and alcohol play a relevant 
role in the pathophysiology of hepatocellular carcinoma (HCC) [59] 
that is the most frequent primary neoplasm of the liver, and is the 
fourth most common malignancy worldwide. It is also the third 
leading cause of cancer-related deaths. However, between 15% and 
50% of HCC develops in the absence of a known etiology of liver 
disease, and different lines of evidence identify in non-alcoholic 
fatty liver disease (NAFLD) a possible relevant risk factor for 
occurrence of HCC. Insulin resistance, steatosis, oxidative stress 
and imbalances in adipokine/cytokine interplay, the most important 
factors involved in NAFLD pathogenesis and progression, could 
also have a determinant role in liver carcinogenesis by promoting 
cellular growth and DNA damage. Recently, behavioral therapy and 
various insulin sensitizing agents have been tested in the treatment 
of NAFLD. A number of studies suggest that these approaches 
improve insulin resistance and reduce steatosis, necroinflammation 
and fibrosis. A potential role of these therapeutic strategies in the 
prevention of hepatocarcinogenesis can thus be envisaged [80].  
 Finally, polyploidization, a state of increased number of 
chromosomes, is recognized as a part of a developmental program. 
Nonetheless, polyploidization also accompanies ageing [81,82]. It 
is believed that tetraploid cells precede aneuploid ones in the early 
phases of tumor development. Division of tetraploid cells is 
restricted by the active tetraploid checkpoint. Tetraploid cells that 
are able to overcome this checkpoint give rise to increased genomic 
instability and tumor progression [83]. Recently, a cellular 
senescence program activated by oncogene expression was shown 
to act as a natural barrier against cancer development. Senescent 
cells were detected in many benign, but not malignant, human and 
animal tumors [84,85]. Senescence can actually block cell 
transformation provided this check-point is active. Cancer cells that 
escaped the checkpoint block are still able to undergo senescence 
upon anticancer treatment. Induction of cancer cell senescence is 
often correlated with high ploidy formation. Some polyploid cells 
can escape senescence and give progeny with numerical changes of 
chromosomes. Divisions of polyploid cancer cells on the road to 
senescence can be responsible for the ineffectiveness of anticancer 
therapy. Altogether, this implies polyploidy as a link between 
cellular senescence, cancer development and possible cancer 
renewal after treatment [86].  
 In time, the better knowledge of the function and the regulation 
of inflammatory pathway in cancer as well as our increasing 
understanding of the molecular mechanisms involved in cancer 
development, including cancer stem cell behavior and regulation of 
cellular senescence pathways, are essential to progress in the design 
of new drugs more specially directed on chemoprevention or 
chemotherapy of human cancers. This strategies could give impor-
tant information for developing better molecular-targeted drugs, 
with minimal side effects, which together with healthier choices of 
nutrition and lifestyles, will help in reducing cancer incidence. 
CARDIOVASCULAR RISK 
 For most of human history, famine and infection have been the 
primary causes of death. Hence, large portions of the human 
genome are devoted to genes involved in cellular metabolism
 
in 
times of crisis (protection from starvation) and in immune-
inflammatory responses (eradication of
 
injury).
 
These interrelated
 
pressures might be expected to select for individuals with mild to 
moderate
 
insulin resistance as well as with relatively
 
enhanced 
inflammatory function. The adaptive pattern of an earlier time has 
resulted in
 
a maladaptive response in our modern environment 
dominated by
 
increasingly sedentary habits, an abundance of high-
carbohydrate
 
foods, and a reduced risk of mortality due to common 
infections. Accordingly, cardiovascular disease is the leading cause 
of death and illness in developed countries. The major contributor 
to cardiovascular disease is atherosclerosis, a progressive, multi-
factorial process that focally affects large arteries and is 
characterized by the accumulation of lipids and fibrous elements in 
their walls. Inflammation is demonstrated to play a crucial role in 
all the phases of the atherosclerotic process, from the initial steps of 
leukocyte recruitment to the eventual rupture of a vulnerable 
plaque. Risk factors for atherosclerosis
 
and adult-onset diabetes 
closely overlap and the fact that the two disorders
 
may derive from 
similar antecedents has
 
lead to a "common soil" hypothesis, which 
suggests, in part,
 
that both of these disorders share a mutual 
inflammatory and
 
perhaps genetic basis. For our hunter/gatherer 
ancestors with a life expectancy of less than 40 years,
 
the advan-
tages of a moderate insulin resistance and a high cytokine responder 
overcame the possible inconveniences of atherosclerosis. In
 
our 
current environment, these inconveniences may prove to be
 
at the 
root of our ongoing epidemic of age-related inflammatory diseases 
[87-92].
  
 Accordingly, several studies have analyzed the association 
between inflammatory gene polymorphisms and atherosclerosis and 
myocardial infarction (MI) [93-95]. In a case-control study on MI, 
SNPs in several inflammatory genes, such as IL-1, IL-6, IL-10, -
1-antichymotrypsin, TNF- and interferon(IFN)- genes along with 
SNPs of genes regulating vascular functions (vascular endothelial 
growth factor; VEGF) and cholesterol synthesis (hydroxymethyl-
glutaryl CoA reductase; HMGCR) were investigated. Patients were 
genotyped and data were analyzed with a new mathematical 
algorithm named Auto Contractive Map (AutoCM). AutoCM was 
applied in MI patients with the aim to detect and evaluate the 
relationships among genetic factors, clinical variables and classical 
risk factors. In the connectivity map generated by AutoCM, a group 
of variables was directly linked with the MI status; these were: 
gender (male), early age at onset (50-65 years), HMGCR gene (CC 
wild type genotype), IL-1CT, IL-6 GG and VEGF CC genotypes. 
This direct link suggested a possible pathogenetic association with 
MI. These analyses suggested that genotypes of few inflammatory 
genes, a SNP in HMGCR gene, middle age, gender, low HDL and 
diabetes were very informative variables to predict the risk of MI 
[96].  
 Cardiovascular diseases are a late consequence of an 
evolutionary pro-inflammatory response programmed to resist 
infections in earlier life. Thus, genetic backgrounds promoting pro-
inflammatory responses may play opposite roles in cardiovascular 
diseases and in longevity. Genetic polymorphisms responsible for a 
low inflammatory response might result in an increased chance of 
longer life span in an environment with a reduced pathogen burden, 
such as a modern-day health environment, which also permits 
obtaining a lower-grade survivable atherogenic inflammatory 
response [93]. In fact, centenarians are reservoirs of genetic and 
environmental information to successful ageing and local cente-
narian groups may help us to understand some of these secrets.  
 In Belfast it is present a centenarian cohort that survived the 
1970s epidemic of death from coronary heart disease in Northern 
Ireland, where cardiovascular mortality was almost highest in the 
world. These centenarians provided an opportunity to assess 
biological and genetic factors important in cardiovascular risk and 
ageing. Thirty-five (27 female, 8 male) centenarians, participants of 
the Belfast Elderly Longitudinal Free-living Ageing Study, were 
community-living and of good cognition at enrolment. Centenarians 
showed median body mass index at 25.7, systolic blood pressure 
140 mmHg and diastolic blood pressure 90 mmHg respectively, and 
fasting glucose of 5.54 mmol/l with no sex-related difference. 
Lipoproteins showed median cholesterol 5.3, HDL 1.10 and LDL 
3.47 umol/l respectively. Centenarian smokers showed no different 
blood pressure or lipid measurements compared with non-smokers. 
Malondialdehyde, a measure of lipid peroxidation, was low at 1.19, 
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and measures of antioxidant status showed variable results. Male 
centenarians did not carry any of the vascular risk genotypes 
studied APOE, Angiotensin-Converting Enzyme and Methylene-
tetrafolatedehydrogenase reductase, though this was not true for 
female centenarians. This small local study shows, apart from age, 
that Belfast centenarians carry a reasonably optimized risk profile 
with respect to cardiovascular disease. There is also some evidence 
suggesting that vascular risk factors and genotypes may be tolerated 
differently between the male and female centenarians. Maintaining 
an optimized cardiovascular risk profile seems likely to improve the 
chance of becoming a centenarian, especially for males [93,97].  
 Ageing is a very complex process highly dependent on the 
interaction between individuals’ genes and the environmental 
factors. Smoking, can be considered an accelerator of ageing, 
capable of affecting molecules, cells and organs of the whole 
human body. This means that smoke compromises not only life 
expectancy, but also the quality of the life, favouring the occurrence 
of non-autonomy. Non-smokers have a much higher life expectancy 
than smokers, and the suspension of smoking is accompanied, even 
in the elderly, by an increase in the survival time due to the 
reduction of smoke-induced biological damage [98]. A lot of 
epidemiologic study support the role of smoke in acute coronary 
syndrome (ACS) and MI. Obesity conferred an elevated risk of 
ACS in both healthy and less healthy subgroups of lifestyle 
behaviors: however, the authors found that obese individuals had a 
considerable lower risk if they were non-smokers [99-101]. Non-
smokers have a much higher life expectancy than smokers, and the 
suspension of smoking is accompanied, even in the elderly, by an 
increase in the survival time due to the reduction of smoke-induced 
biological damage. Today numerous quitting strategies exist, either 
of pharmacological or non-pharmacological type, which are also 
advantageous for the elderly person [98]. 
 As previously stated, TLRs are principal mediators of rapid 
microbial recognition and function mainly by detection of 
pathogen-associated molecular patterns that do not exist in the host. 
Recognition of their ligands leads to a series of signaling events 
resulting in acute host responses, involved in killing pathogens. 
Until now, 13 mammalian TLR members have been identified. 
Each TLR appears to recognize distinct pathogen-associated 
molecular patterns, derived from various microorganisms, including 
bacteria, viruses, protozoa and fungi. Recognition of their ligands 
leads to a series of signaling events resulting in acute host 
responses, involved in killing pathogens. One of the best 
understood TLR members is TLR-4, involved in recognition of the 
lipopolysaccharide (LPS) [22]. 
 A couple of papers have analysed the effects of LPS on 
embryonal cardiomyocites wich may constitute a valid experi-
mental model in order to study LPS-induced inflammatory 
responses [102,103]. Results emerging from these studies suggest 
the existence of two signalling pathways induced by LPS treatment: 
an inflammatory response sustained by NF-B leading to TNF- 
and NO release, and an anti-inflammatory response due to COX-2 
activation. So, both NF-B and COX-2 act as two key molecules 
able to determine the cell fate. The balance between pro and anti- 
inflammatory responses ultimately may protect cardiomyocytes 
from an excessive cell loss deriving by endotoxin stress. Further 
characterization of these pathways could provide a wealth of 
information about the responses of cardiac cells to endotoxin stress, 
in order to identify pharmacological targets for heart protection 
during sepsis. At the same time, the immunocompromised host and, 
in particular, aged people are exposed to bacterial toxic products 
more than healthy population, and, therefore, detrimental effects on 
the heart should be taken into serious consideration by clinicians 
[102]. 
 Furthermore, LPS-induced inflammatory response by cardio-
myocytes is useful not only to identify the signalling pathways 
evoked by endotoxin receptor, including TLR-4, but also to suggest 
therapeutic targets for the control of myocardial dysfunction 
induced by infectious agents. In this respect, in elderly a continuous 
leakage of LPS from gut flora and/or external environment should 
be regarded as a possible cause of cardiac failure and, therefore, 
adequately prevented or treated [103]. 
 Finally, a study on a cohort of Italian Caucasians comprising 
490 type 2 diabetic and 349 control subjects investigated whether 
the -1087G/A (rs1800896), -824C/T (rs1800871), -597C/A 
(rs1800872) IL10 polymorphisms were associated with type 2 
diabetes [104]. Stratifying the data according to IL-10 genotypes, 
trends for the progressive increase of glucose and neutrophil levels 
were observed in -1087GG vs. -1087GA vs. -1087AA positive 
diabetic patients (-1087GG<-1087GA<-1087AA). In addition, 
evaluating the laboratory parameters according to the -597/-824/-
1087 derived haplotypes a significant increase of neutrophils was 
found in diabetic vs. non-diabetic -597A/ -824T/-1087A positive 
subject. In an attempt to integrate clinical laboratory and immu-
nogenetic data to determine whether these factors taken together 
define sufficient risk sets for type 2 diabetes we performed the 
grade-of-membership analysis (GoM). GoM allowed to identify a 
population of subjects negative for IL-10 -824T allele, 74.4% of 
which were diabetic patients characterized by vascular damages, 
reduction of haematocrit, increase of blood urea nitrogen, creatinin 
and monocyte levels. These data seem to suggest that -597A/-
824T/-1087A negative subjects are more prone to the major type 2 
diabetic vascular damages and allow to hypothesis that the 
contemporary evaluation of some simple hemato-chemical para-
meters and IL-10 SNPs may allow identifying diabetic patients with 
the worse prognostic profile, needing both better complication 
prevention planning and therapeutic strategies [104].  
 Some of the studies here outlined allow building a risk profile 
that potentially enables the early identification of individuals 
susceptible to disease and the possible design or use of drug at the 
right dose for a desired effect, that is, a pharmacogenomic approach 
for a given disease [40,94]. 
LONGEVITY 
 The majority of above described immune-inflammatory aspects, 
that characterize ageing, are also detectable in extreme longevity, 
where a higher frequency of genetic markers associated with a 
reduced pro-inflammatory ability seems to counteract the onset of 
the main age-related inflammatory disorders. The data on the 
determinants of human longevity indicate that centenarians are a 
good choice for the study of longevity, because they represent an 
extreme phenotype, i.e., the survival tail of the population who 
escaped neonatal mortality, pre-antibiotic era illnesses, and fatal 
outcomes of age-related complex diseases. Centenarians are quite 
capable of mounting effective inflammatory responses; however, 
inflammatory status, correlated to increasing risk of developing 
frailty and diseases, is compensated by the concomitant develop-
ment of strong and effective anti-inflammatory responses 
[24,25,105]; (see also above). Hence, the study of centenarians 
allows us to correlate longevity and some of the major age-related 
pathologies. Centenarians are remarkably enriched in “good” 
genotypes and show opposite frequencies of “bad” genotypes in 
comparison with patients affected by major age-related pathologies, 
such as cardiovascular disease, AD and cancer. So, they can be 
considered as “super-controls”, allowing a reliable and accurate 
identification of the variants related to the major killer and as a 
further proof that longevity is, at least in part, the positive 
counterpart of unsuccessful ageing [24,59,61,62, 93,97,105-108]. 
 A study on a group of nonagenarians has been performed in 
order to follow-up their survival [109]. The involvement of Hsp70 
in cellular maintenance and repair mechanisms, including its role as 
an anti-inflammatory protein, makes it a suitable candidate for 
studying such associations [110-112]. Three single nucleotide 
polymorphisms, HSPA1A (-110A>C), HSPA1B (1267A>G), and 
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HSPA1L (2437T>C), present in the three HSP70 genes, were 
studied in a cohort of individuals born in the year 1905. This 
population cohort is a part of the longitudinal study of Danish 
nonagenarians. Since DNA samples were already collected in 1998, 
this gave them the opportunity to perform survival analysis on these 
subjects. Haplotype relative risk, and genotype relative risk were 
calculated to measure the effects of haplotypes and genotypes on 
human survival in a sex-specific manner. A significant association 
of HSPA1A-AA and HSPA1B-AA genotypes with poor survival 
was observed in female subjects. Also the female carriers of 
haplotype G-C-T had longer survival than the non-carriers. On an 
average, female carriers of the G-C-T haplotype live about one year 
longer than non-carriers. These results from the association of 
genotypes/haplotypes of HSP70 genes on human survival reiterate 
the view that the genes involved in stress response (and 
inflammation) are involved in the genetics of longevity [109]. 
 Human ageing and longevity are complex and multi-factorial 
traits that result from a combination of environ-mental, genetic, 
epigenetic and stochastic factors, each contributing to the overall 
phenotype. The multi-factorial process of ageing acts at different 
levels of complexity, from molecule to cell, from organ to organ 
systems and finally to organism, giving rise to the dynamic “ageing 
mosaic”. At present, an increasing amount of experimental data on 
genetics, genomics, proteomics and other -omics are avail-able 
thanks to new high-throughput technologies but a comprehensive 
model for the study of human ageing and longevity is still lacking 
[3,61,107,113-116]. Hence, system biology has been suggested to 
be a powerful tool to integrate and quantify high dimensionality but 
still fragmented data that are produced by increasing high-
throughput technologies in the field of genomics, proteomics, 
metabolomics and other -omics [117]. It is proposed that a 
comprehensive analysis of this information is possible only through 
a systems biology approach, in a recursive process of “wet” and 
“dry” experiments. Actually, the existing information and new data 
generated by ad hoc experiments are put together in a com-
prehensive data set, which is then analyzed and used to generate 
predictive mathematical models. These new models can suggest 
new experiments, which in turn produce an enlarged data set and 
the analytic process restarts. This innovative approach can be 
performed only if specific expertise of analysis and computational 
power will be available, joint to more collaboration across disci-
plines and countries. This integrated approach will let us understand 
the ageing process at organism level and to identify targets for anti-
ageing interventions [117]. 
 However, data on centenarians discussed in the present paper 
suggest that “healthy ageing” is a real possibility for human beings 
and cast some doubt on the pessimistic view that extreme age must 
always be accompanied with severe diseases and/or disabilities. 
DIET AND AGEING 
 In the elderly, nutrition monitoring in the elderly, and food 
consumption have the
 
potential for dropping the rate of chronic 
diseases and improving quality
 
of life by providing specific 
information to aid in the development
 
of targeted dietary and other 
intervention strategies. In fact, many, if not all, age-related diseases 
are, partly preventable by diet and exercise, understanding the 
feasibility of good nutrition and the need to achieve and maintain a 
healthy weight [118]. Nowadays, it is known how minerals, 
vitamins, microelement deficiency can strongly influence the onset 
and the path of many chronic inflammatory degenerative disease. 
Eating well means ageing fine and delay, if not avoid, disease like 
diabetes type II, hypertension, obesity, cardiovascular disease and 
also, at least in part, osteoporosis and cancer. Therefore, it is 
important to identify dietary patterns and supplements, in addition 
to specific dietary components, in order to offer shelter against 
many chronic inflammatory disease. Furthermore, ageing is 
associated with frailty and malnutrition which direct consequences 
are leading to increased risk of many geriatric syndromes such as 
falls, delirium, functional decline and depressed immunity [119]. 
Recent studies found that frailty clinical phenotype is associated 
with pathologic laboratory markers suggesting a possible patho-
genesis involving hormonal dysregulation, immunosenescence, pro-
coagulation and pro-inflammatory status [120]. All the above 
pathways might be regulated and influenced by nutritional inter-
vention upon administration of micronutrients, food supplemen-
tation and functional food. 
 "Let food be the medicine and medicine
 
be the food" was 
embraced 2500 years ago by Hippocrates and this tenet has 
acquired more audience in the last years with an ageing, health-
conscious population, several changes in food
 
regulations, techno-
logical advances and a marketplace
 
ripe for the introduction of 
health-promoting products, know as "functional
 
foods and food 
supplementation."  
 As an example, substance like berries have been recognized 
since the 1920s for their efficacy
 
in treating urinary tract infections. 
More recent research has
 
confirmed that condensed tannins 
(proanthocyanidins) in berries
 
are the biologically active component 
and prevent E. coli from
 
adhering to the epithelial cells lining the 
urinary tract. Moreover, additional beneficial effects of berries 
include enhancement of neuronal communication via increases in 
neuronal signaling and decreases in stress signals induced by 
oxidative/inflammatory stressors (e.g., NF-B). Moreover, blue-
berry or concord grape juice supplementation in humans with mild 
cognitive impairment increased verbal memory performance. Taken 
together, these results suggest that a greater intake of high-
antioxidant foods such as berries, concord grapes, and walnuts may 
increase “health span” and enhance cognitive and motor function in 
ageing [121]. 
 Food supplementation are essential elements needed by life in 
different quantities. They include microminerals, fatty acid, fiber 
and vitamins. Microminerals or trace elements include at least iron, 
cobalt, chromium, copper, iodine, manganese, selenium, zinc, and 
molybdenum. Many of these element have different capacities 
ranging from anti-oxidative stress to immunity regulation to chronic 
inflammatory disease regulation [122]. Functional foods are foods 
characterized for their added physiologic benefits, which may
 
reduce chronic disease risk or otherwise optimize health. They 
represent the whole bench of substances covering potentially 
healthful products including any modified food or ingredient that 
may provide a benefit beyond the traditional nutrients. They 
comprise food like cereals, milk and breads and beverages which 
are fortified with vitamins and herbs. Among these we have also 
vitamins, herbal extracts, amino acids, polyamine, minerals and 
probiotics [122]. They are sold on the market as foods for general 
consumption (or ''health foods'') to be used as ''supplements'' to 
nutrition (diet). 
 Among others, one of the most known functional food is a class 
of biologically active components,
 
that has received increasing 
attention in recent years, called probiotics and defined as "viable 
microorganisms that are beneficial to human
 
health" [9,123]. They 
are, usually, microorganism already living in the intestine district 
such as Bifidobcteria, Enterococci and Lactobacilli. Several 
scientific works support the utilize of these functional ingredients 
for various health
 
concerns including cancer, intestinal tract 
function, immune
 
function, allergy, stomach health, urogenital 
health, cholesterol
 
lowering and hypertension [9,124-126].  
 Substance like polyamines that seem to be affected by 
probiotics like Lactobacilli are quite interesting in this area because 
associated with cancer risk. These substances play an essential role 
in cell proliferation because cells produce their own internally, and 
they gather circulating polyamines that come from dietary sources, 
such as intestinal bacteria, and those excreted by other cells. Cells 
depend on polyamines for growth and their depletion represents a 
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strategy for the treatment of cancer. In vitro Lactobacilli have 
shown to affect polyamine content on gastric cancer cells and in 
vivo significantly decrease the polyamine biosynthesis in pre-
neoplastic condition [125-127]. 
 Another substance that seems playing an important role in 
cancer is Curcumin, which is a phytochemical derived from 
rhizome of Curcuma Longa present in the spice turmeric that gives 
Indian curry its yellow colour. Curcumin seems to have effect as 
anti-inflammatory, anti-oxidant and against cancer. In this respect it 
looks influencing transcription factors, cyclin E and D and several 
growth factors. It is also a potent inducer of cell death including 
apoptosis, mitotic catastrophes and autophagy [128].  
 As discussed, inflammation is the hallmark of many age-related 
pathologies. Life style and nutrition can influence progress and 
dimming of the inflammatory status as for example controlling 
obesity, known as an inflammatory process mediated by soluble 
products released by both immune cells and adipocytes. Leptin, 
adiponectin and visfatin are the major adipocytokines in addition to 
classical cytokines such as TNF-, IL-1, IL-6, produced by adipo-
cytes [129,130]. It is important as various food supplementation and 
functional food can have a role in switching-of the inflammatory 
pathway [130]. Lipoic acid is an essential cofactor for mito-
chondrial respiratory enzyme and has been shown to have potent 
anti-obesity properties in animals. It seems that its role is to guide a 
cross-talk between adipose tissue and skeletal muscle, mediating by 
the reduction of TNF- and IL-6 production [131]. 
 The benefit of the Mediterranean diet has been seen in healthy 
preobese/obese patients, since, as it is known, adipose tissue closely 
correlated with type II diabetes and coronary heart disease due to a 
low grade systemic inflammation. In fact a diet rich in fruit, 
vegetables, legumes, whole grains, fish, and low-fat dairy products 
are associated with lower incidence of various chronic diseases, as 
atherosclerosis, cardiovascular diseases, and cancer [132].  
 Inulin belongs to the class of carbohydrates know as fructans 
and it has been studied in the contest of lipid lowering effect and 
therefore having a great influence on cardiovascular disease. Inulin-
enriched pasta rises an increased interest because able modifying 
some of the metabolic risk factors for dysmetabolic diseases. 
Importantly, data in this issue suggest that inulin may positively 
modify glucose homeostasis, as demonstrated by the significant 
effects on fasting glucose levels, fructosamine, and HbA1c [133].  
 Donkey milk has been seen as an enhancer of acute phase 
response and to a lesser extent, of proinflammatory cytokine 
response while goat milk is rather a down regulator of acute 
inflammation, thus preventing massive infiltration of neutrophils 
into the senescent lung and, consequentially further damage to vital 
organs. Goat’s milk seems to trigger gut macrophages to release 
NO which in turn seems to have cardioprotective, antiatherogenic 
and antibacterial effect contributing to longevity and at the same 
time regulate inflammatory cytokines and stimulate IgA at mucosal 
level. Moreover both donkey and goat milk seems to posses the 
capacity to modulate immunity through the stimulation of IFN-, 
lysozime, mucin, oligosaccarides, fatty acid, hormones and growth 
factors [134,135]. 
 Also minerals like magnesium seems to have an important role 
in inflammation. Hypomagnesemia has been associated with 
inflammation and increased production of ROS. Poor magnesium 
status may trigger the development of a proinflammatory state both 
by causing excessive production and release of IL-1 and TNF-, 
and by elevating circulating concentrations of proinflammatory 
neuropeptides that trigger activation of low-grade chronic 
inflammation [136]. So a supplementation of magnesium seems to 
be of a help in human health. Sarcopenia, a typical ageing event, is 
strictly associated with loss of function, disability, malnutrition and 
hospitalization. Several studied have shown that magnesium deple-
tion strongly impaired muscle performance [136]. As discussed, 
immunity plays a paramount role in ageing and inflammatory 
chronic disease therefore being able to trigger or influence innate or 
acquired immunity by micronutrient administration can be a tool to 
use close to generic medicine [2,9]. Once again magnesium, seems 
involved in immune component production like in immuno-
globulin synthesis, C3 convertase, immune cell adherence, antibody 
dependent cytolysis, IgM lymphocyte binding and T helper  cell 
adherence [136].  
 Long-term oxidative stress is believed to be one of the major
 
factors contributing to ageing. The oxidative stress results from the 
shift toward ROS production in the equilibrium between ROS 
generation and the antioxidant defence. Oxygen free radicals as 
well as reactive nitrogen species (RNS), are products of normal 
cellular metabolism playing a dual role as both deleterious and 
beneficial species, since they can be either harmful or beneficial to 
living systems. The advantageous effects of ROS take place at low 
or moderate concentrations and imply their physiological roles in 
cellular responses to noxa, defence against infectious agents, 
cellular signaling and induction of a mitogenic response. The 
damaging effect occurs in biological systems when there is an 
overproduction of ROS/RNS on one side and a deficiency of 
enzymatic and non-enzymatic anti-oxidants on the other side. The 
harmful effect of redox regulation implicated diseases including 
cancer, diabetes mellitus, ischemia/reperfusion injury, inflam-
matory diseases, neurodegenerative disorders and ageing [137-140].  
 There are several compound described in literature recognized 
as antioxidant like vitamins and flavonoids. Among others it comes 
clear from literature that magnesium, in sufficient amount, prevents 
oxygen radicals formation by scavenging free radicals and 
inhibiting xanthine oxidase and nicotinamide adenine dinucleotide 
phosphate oxidase. In animal model low magnesium intake is 
associated with superoxide dismutase, hepatic glutathione and 
vitamin E decrease and increase of lipid peroxidation and malon-
dialdehyde. Lipoic acid  has the ability to scavenge ROS and 
influence the tissue concentration of lipoate. Alpha-lipoic acid have 
other antioxidant properties including chelation of transition metals 
and the regeneration of other antioxidants such as glutathione, 
vitamin C and vitamin E [131,136,141]. 
 Although there is evidence that certain functional foods or
 
food 
ingredients can play a role in disease prevention and health
 
promotion, safety considerations should be paramount. Safety
 
concerns have recently been raised, particularly with regard
 
to the 
seemingly indiscriminate addition of botanicals to foods.
 
A plethora 
of "functional" bars, beverages, cereals and soups
 
are being 
enhanced with botanicals, some of which may pose a
 
risk to certain 
consumers. The safety issues related to herbs
 
are complex and the 
issue of herb-drug interaction has received
 
increasing attention 
CONCLUSION 
 Nowadays, many countries have rising ageing populations and 
are facing an increased prevalence of age-related diseases and 
increasing healthcare costs. During the 20th century, life expec-
tancy at birth rose by a remarkable 30 years in developed countries, 
initially because of reductions in infant, child, and maternal 
mortality and then because of declining mortality in middle and old 
age. In 1900, about 40% of babies born in countries for which 
reliable data existed were expected to live beyond age 65. Today in 
these same countries more than 88% of all newborns will live past 
age 65 and at least 44% will live beyond age 85 [142-144]. How-
ever, the rapid rise in older people is accompanied by an increase in 
the number of people with chronic age-related diseases previously 
discussed. Elderly are less resistant to both environmental and 
pathological injury; in addition, they are less resistant to infection. 
Hence, the time has come to get more serious about the effort to 
slow human ageing or, on the other hand, to age successfully. In 
fact, success in increasing longevity in laboratory organisms has 
shown that ageing is not an immutable process [145,146]. It has 
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been calculated that if ageing is slowed for seven years, the age 
specific risk of death, frailty, and disability will be reduced by 
about half at every age. People who reach the age of 60 in the future 
would resemble current 53 year olds, and so on. On the other hand, 
if ageing is combined with extended years of healthy life, it could 
also produce unprecedented social, economic, and health dividends 
[146,147]. 
 Understanding of the ageing process should be a crucial 
component of such innovations and must have a prominent role in 
new strategies for extending the health of a population that is highly 
susceptible to the diseases of ageing [146]. Accordingly, as exten-
sively discussed in the review and in the accompanying related 
papers, investigating ageing pathophysiology, particularly disen-
tangling low grade inflammation, is likely to provide important 
clues about how to develop drugs that can slow or delay ageing 
[148]. 
ABBREVIATIONS 
A = -amyloid 
Ach = Acetylcholine 
ACS = Acute Coronary Syndrome 
AD = Alzheimer's disease 
AutoCM = Auto Contractive Map 
COX = Cyclo-oxygenase 
GoM = Grade-of-membership analysis 
Hsp70 = Heat shock protein 70 
HCC = Hepatocellular Carcinoma 
HMGCR = Hydroxy-Methyl-Glutaryl CoA Reductase 
IFN = Interferon 
IL = Interleukin 
LO = Lipo-oxygenease 
LPS = Lipopolysaccharide 
MI = Myocardial Infarction 
NFTs = Neurotrophic Factors 
NSAIDs = Mon-Steroidal Anti-Inflammatory Drugs 
NBM = Nucleus Basalis Magnocellularis 
OA = Osteoarthritis 
PD = Periodontitis 
Pca = Prostate cancer 
RNS = Reactive Nitrogen Species 
ROS = Reactive Oxygen Species 
SNPs = Single Nucleotide Polymorphisms 
TLRs = Toll-like Receptors 
TNF = Tumor Necrosis Factor 
VEGF = Vascular Endothelial Growth Factor 
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